

ASX Announcement

20 March 2025

Results of General Meeting

Melbourne, Australia – Tryptamine Therapeutics Limited (**'Tryp'** or the **'Company'**) (**ASX: TYP**), a clinical-stage biopharmaceutical company, is pleased to advise that Shareholders of the Company passed at the General Meeting held today all Resolutions by poll as set out in the Notice of Meeting announced to the ASX on 13 February 2025.

In accordance with ASX Listing Rule 3.13.2 and Section 251 AA(2) of the Corporations Act, a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached.

This announcement has been authorised for release by the Chair of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead asset, TRP-8803, is a proprietary, scalable and innovative formulation of IV-infused psilocin (the active metabolite of psilocybin) with neuroplastic benefits. It has the potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the neuroplastic state, controlling the depth and duration of the neuroplastic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a successful clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Investor & media enquiries:

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law by law.

Disclosure of Proxy Votes

Tryptamine Therapeutics Limited

General Meeting

Thursday, 20 March 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of Prior Issue of Tranche 1 Shares to Non-Related Parties	P	112,818,437	112,709,748 99.90%	70,689 0.06%	0	38,000 0.03%	112,756,148 99.94%	70,689 0.06%	0	Carried
2 Approval of Issue of Tranche 2 Shares to Non-Related Parties	P	120,768,437	120,626,598 99.88%	103,839 0.09%	0	38,000 0.03%	120,672,998 99.91%	103,839 0.09%	0	Carried
3 Approval of Issue of Unlisted Options to Non-Related Parties	P	112,818,437	112,561,598 99.77%	218,839 0.19%	0	38,000 0.03%	112,607,998 99.81%	218,839 0.19%	0	Carried
4 Approval of Issue of Tranche 2 Shares and Unlisted Options to Mr Chris Ntoumenopoulos, Director of the Company	P	120,768,437	118,504,784 98.13%	2,082,489 1.72%	0	181,164 0.15%	118,694,348 98.28%	2,082,489 1.72%	0	Carried
5 Approval of Issue of Tranche 2 Shares and Unlisted Options to Mr Jason Carroll, CEO and Executive Director of the Company	P	78,468,437	78,184,784 99.64%	102,489 0.13%	42,300,000	181,164 0.23%	78,374,348 99.87%	102,489 0.13%	42,300,000	Carried
6 Approval of Issue of Tranche 2 Shares and Unlisted Options to Dr Daniel Tillett, Director of the Company	P	108,768,437	108,369,784 99.63%	217,489 0.20%	0	181,164 0.17%	108,559,348 99.80%	217,489 0.20%	0	Carried
7 Approval of Issue of Director Options to Dr Daniel Tillett, Director of the Company	P	108,768,437	108,369,784 99.63%	217,489 0.20%	0	181,164 0.17%	108,559,348 99.80%	217,489 0.20%	0	Carried
8 Approval of Issue of Lead Manager Options	P	120,768,437	120,369,784 99.67%	217,489 0.18%	0	181,164 0.15%	120,559,348 99.82%	217,489 0.18%	0	Carried

